Protocol Reference — Inflammation Reduction

BPC-157 — safe default

250 mcg/day, 6 weeks on, 4 weeks off

Cycle to avoid receptor desensitisation.

BPC-157 — experimental

500 mcg twice daily for up to 12 weeks

Outside routine clinical practice; no Phase III safety for this range.

ARA-290 — safe default

1 mg SubQ, 3× weekly for 4 weeks

Mirrors sarcoidosis SFN Phase II dosing schedule.

ARA-290 — experimental

4 mg SubQ or IV daily for up to 12 weeks

Investigational dosing; not an approved regimen.

KPV — safe default

200 mcg/day (oral or SubQ) for 4 weeks

Short cycle consistent with preclinical inflammation models.

KPV — experimental

500 mcg twice daily for up to 8 weeks

No human dosing standard exists.

TB-500 / Tβ4 — safe default

2 mg SubQ twice weekly

Maintenance framing.

TB-500 / Tβ4 — experimental loading

4–8 mg weekly for 1–4 weeks, then 2–6 mg monthly maintenance

Common practitioner pattern; no regulatory endorsement.